Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA

Gene therapy provides an opportunity to ameliorate several genetic disorders and treat numerous diseases by using nucleic acid-based materials to modulate gene activity. However, the greatest challenge for successful gene therapy applications remains delivery. Two general approaches are currently un...

Full description

Bibliographic Details
Main Author: Fernandez, Christian Antonio
Other Authors: Rice, Kevin G.
Format: Others
Language:English
Published: University of Iowa 2010
Subjects:
Online Access:https://ir.uiowa.edu/etd/800
https://ir.uiowa.edu/cgi/viewcontent.cgi?article=1985&context=etd
id ndltd-uiowa.edu-oai-ir.uiowa.edu-etd-1985
record_format oai_dc
spelling ndltd-uiowa.edu-oai-ir.uiowa.edu-etd-19852019-10-13T04:33:15Z Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA Fernandez, Christian Antonio Gene therapy provides an opportunity to ameliorate several genetic disorders and treat numerous diseases by using nucleic acid-based materials to modulate gene activity. However, the greatest challenge for successful gene therapy applications remains delivery. Two general approaches are currently under investigation to improve gene delivery efficiencies. The first is by encapsulating therapeutic genes into modified viruses that are effective at transfecting cells but that have also caused serious side effects during clinical evaluations in 1999 and 2003. In contrast, non-viral gene therapy provides the safety of conventional pharmaceutical products, but possesses inadequate transfection efficiencies for clinical use. Successful non-viral gene delivery systems require evasion of the reticuloendothelial system (RES) while in circulation, a targeting ligand for efficient cellular uptake, and perhaps several additional components for efficient cellular disposition once the carrier has been internalized. Engineering sophisticated gene delivery systems requires modular designs that are well characterized and optimized to circumvent each limiting barrier associated with gene delivery. The following thesis is focused on developing stabilized DNA polyplexes for in vivo applications and coupling their administration with current physical methods of non-viral gene delivery. The aim behind this approach is to systematically prepare gene carriers and evaluate their ability to maintain DNA transfection competent in order to determine which bioconjugate is the most successful for ultimately creating gene carriers that do not require physical interventions for gene expression. The non-viral gene delivery systems presented in the thesis are based on PEGylated polyacridine peptides that bind to DNA predominantly by intercalation rather than by ionic interactions with DNA. The initial experimental chapters deal with the discovery of these novel DNA polyplexes, and the latter chapters focus on the optimization of their design for targeted in vivo gene delivery. The results demonstrate that PEGylated polyacridine DNA polyplexes possess improved compatibility for in vivo administration and that their flexible design is beneficial for preparing multi-component gene delivery systems. 2010-12-01T08:00:00Z dissertation application/pdf https://ir.uiowa.edu/etd/800 https://ir.uiowa.edu/cgi/viewcontent.cgi?article=1985&context=etd Copyright 2010 Christian Antonio Fernandez Theses and Dissertations eng University of IowaRice, Kevin G. Acridine Drug Delivery Gene Therapy Pharmacokinetics Plasmid DNA Polyplex Pharmacy and Pharmaceutical Sciences
collection NDLTD
language English
format Others
sources NDLTD
topic Acridine
Drug Delivery
Gene Therapy
Pharmacokinetics
Plasmid DNA
Polyplex
Pharmacy and Pharmaceutical Sciences
spellingShingle Acridine
Drug Delivery
Gene Therapy
Pharmacokinetics
Plasmid DNA
Polyplex
Pharmacy and Pharmaceutical Sciences
Fernandez, Christian Antonio
Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
description Gene therapy provides an opportunity to ameliorate several genetic disorders and treat numerous diseases by using nucleic acid-based materials to modulate gene activity. However, the greatest challenge for successful gene therapy applications remains delivery. Two general approaches are currently under investigation to improve gene delivery efficiencies. The first is by encapsulating therapeutic genes into modified viruses that are effective at transfecting cells but that have also caused serious side effects during clinical evaluations in 1999 and 2003. In contrast, non-viral gene therapy provides the safety of conventional pharmaceutical products, but possesses inadequate transfection efficiencies for clinical use. Successful non-viral gene delivery systems require evasion of the reticuloendothelial system (RES) while in circulation, a targeting ligand for efficient cellular uptake, and perhaps several additional components for efficient cellular disposition once the carrier has been internalized. Engineering sophisticated gene delivery systems requires modular designs that are well characterized and optimized to circumvent each limiting barrier associated with gene delivery. The following thesis is focused on developing stabilized DNA polyplexes for in vivo applications and coupling their administration with current physical methods of non-viral gene delivery. The aim behind this approach is to systematically prepare gene carriers and evaluate their ability to maintain DNA transfection competent in order to determine which bioconjugate is the most successful for ultimately creating gene carriers that do not require physical interventions for gene expression. The non-viral gene delivery systems presented in the thesis are based on PEGylated polyacridine peptides that bind to DNA predominantly by intercalation rather than by ionic interactions with DNA. The initial experimental chapters deal with the discovery of these novel DNA polyplexes, and the latter chapters focus on the optimization of their design for targeted in vivo gene delivery. The results demonstrate that PEGylated polyacridine DNA polyplexes possess improved compatibility for in vivo administration and that their flexible design is beneficial for preparing multi-component gene delivery systems.
author2 Rice, Kevin G.
author_facet Rice, Kevin G.
Fernandez, Christian Antonio
author Fernandez, Christian Antonio
author_sort Fernandez, Christian Antonio
title Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
title_short Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
title_full Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
title_fullStr Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
title_full_unstemmed Development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA
title_sort development of pegylated polyacridine peptides for in vivo gene delivery of plasmid dna
publisher University of Iowa
publishDate 2010
url https://ir.uiowa.edu/etd/800
https://ir.uiowa.edu/cgi/viewcontent.cgi?article=1985&context=etd
work_keys_str_mv AT fernandezchristianantonio developmentofpegylatedpolyacridinepeptidesforinvivogenedeliveryofplasmiddna
_version_ 1719264267867258880